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ABSTRACT
SnowShoes-FTD, developed for fusion transcript
detection in paired-end mRNA-Seq data, employs
multiple steps of false positive filtering to
nominate fusion transcripts with near 100% confi-
dence. Unique features include: (i) identification of
multiple fusion isoforms from two gene partners; (ii)
prediction of genomic rearrangements; (iii) identifi-
cation of exon fusion boundaries; (iv) generation of a
50–30 fusion spanning sequence for PCR validation;
and (v) prediction of the protein sequences,
including frame shift and amino acid insertions.
We applied SnowShoes-FTD to identify 50 fusion
candidates in 22 breast cancer and 9 non-
transformed cell lines. Five additional fusion candi-
dates with two isoforms were confirmed. In all, 30 of
55 fusion candidates had in-frame protein products.
No fusion transcripts were detected in non-
transformed cells. Consideration of the possible
functions of a subset of predicted fusion proteins
suggests several potentially important functions in
transformation, including a possible new mechan-
ism for overexpression of ERBB2 in a HER-positive
cell line. The source code of SnowShoes-FTD is
provided in two formats: one configured to run on
the Sun Grid Engine for parallelization, and the other
formatted to run on a single LINUX node.
Executables in PERL are available for download
from our web site: http://mayoresearch.mayo.edu/
mayo/research/biostat/stand-alone-packages.cfm.
INTRODUCTION
Gene fusion events resulting from inversions, interstitial
deletion or translocations represent one of the most
common types of genomic rearrangement (1). So far, the
majority of fusion genes have been identiﬁed in leukemias,
lymphomas and sarcomas. Recently, the discovery of
TMPRSS2-ERG fusions in prostate cancer (2) and
EML4-ALK fusion in non-small-cell lung tumors (3)
suggests that gene fusion events may as well occur with
a relatively high frequency in solid tumors, leading to the
generation of novel fusion proteins with unique oncogenic
properties. Since these fusion gene products are mainly
restricted to tumor cells, they constitute potentially
useful diagnostic and therapeutic targets. For example,
the BRC-ABL1 fusion gene has been a diagnostic
marker for chronic myelogenous leukemia (CML), as
well as the drug target of Imatinib (Gleevec) in cells that
harbor the BRC-ABL1 fusion gene. In addition, the iden-
tiﬁcation of fusion gene products in solid tumors may
yield new insight into the etiology of certain tumors.
The prostate cancer-speciﬁc TMPRSS2-ERG fusion
events place growth regulatory genes under the inﬂuence
of an androgen-regulated promoter, giving rise to a novel
oncogene that has the potential to amplify normal
androgen-dependent growth (2).
Identiﬁcation and validation of fusion genes or their
products in solid tumors have been challenging, largely
due to the technical limitations inherent in techniques
such as comparative genomic hybridization, ﬂuorescent
in situ hybridization, cytogenetic analysis and spectral
karyotyping. However, the combination of bioinformatics
approaches for the identiﬁcation of fusion candidates
followed by reverse-transcriptase PCR validation of the
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and massive parallel RNA sequencing (RNA-Seq) data
(4–7). Specially, the recent advances in RNA-Seq using
next-generation sequencers have opened new horizons
on the identiﬁcation of expressed fusion transcripts.
Four very recent publications substantiated the power of
this approach. The use of long sequencing reads (median
length of  250 bases) generated by the Roche 454 sequen-
cer identiﬁed 9 chimeric mRNAs in the HCC1954 breast
cancer cell line in which all fusion transcripts were subse-
quently veriﬁed by Sanger re-sequencing of genomic DNA
(8). Zhao et al. used an earlier version of the Roche 454
sequencer to generate reads of median length 88 nt from a
primary breast cancer sample (9) and identiﬁed 6 putative
gene fusion events, one of which involved UBR4 (ubiqui-
tin protein ligase E3 component n-recognin 4, chr1) and
GLB1 (beta-galactosidase-like protein, chr3). UBR4, also
known as RB1-associated p600, is a cellular target of
human papilloma virus E7 oncoprotein and is involved
in anchorage-independent growth and transformation
(10). Two studies from the Chinnaiyan group at the
University of Michigan took advantage of the higher
throughput, lower cost, short reads from the Illumina
Genome Analyzer (IGA). The ﬁrst of the two studies ini-
tially used the long read capacity of the Roche 454 sequen-
cer to generate a reference library which was then
interrogated using short reads (36-base) from the IGA
(5). With this approach, the study ‘re-discovered’ the
BCR-ABL1 and TMPRSS2-ERG in CML and prostate
cancer cell lines, respectively. In addition, the authors
identiﬁed and validated a number of novel fusion gene
products in prostate cancer cells including several hereto-
fore unknown ETS gene fusion products. Although the
initial Chinnaiyan paper represents a landmark in the
use of next-generation sequencers to identify fusion gene
products, the authors noted several drawbacks related to
the approaches used in the study. The ﬁrst and most
obvious is the overhead associated with the need to
analyze each sample with two different platforms (Roche
454 and IGA). Also, the short read length gave rise to a
high false discovery rate (FDR), which was not entirely
eliminated by the application of a number of informatics
ﬁlters. A later paper from the same group described the
use of paired-end sequencing to identify fusion gene
products in tumor cell lines (6). Brieﬂy, this approach
involves the generation of RNA-Seq libraries which
contain different adaptors on the 50- and 30-ends of the
cDNA fragments. The IGA was then used to carry out
sequencing from each end of 16–25 million cDNA frag-
ments (50-base from each end). Reads whose two ends
mapped to transcripts from two different genes (fusion
encompassing reads) are indicative of fusion events,
which are supported by the reads whose one end
mapped to one of the fusion partners and the other end
spanning the fusion junction point (fusion junction
spanning reads). In the same paper, the paired end deep
sequence analysis was extended to MCF7 cells to identify
fusion gene products. The analysis identiﬁed
BCAS4-BCAS3 and ARFGEF2-SULF2, which had previ-
ously been described in MCF7 cells (11), as well as several
novel fusion transcripts. Two recent publications have
extended the use of paired-end sequencing data to
identify fusion gene transcripts in cell lines, including the
analysis of fusion gene products in a small group of breast
cancer cells (4,12).
All the bioinformatics methods for fusion discovery in
transcriptome sequencing data described in the recent
publications incorporated steps of false positive ﬁltering
and identiﬁed novel fusion transcripts in various types of
solid tumors or cancer cell lines. However, only Sboner
et al. (7) made their bioinformatics tool publicly available.
In addition, all published bioinformatics algorithms stop
at the nomination of fusion candidates, while the
follow-up analyses including fusion validation and
studying of the structural details of the fusion transcripts
still require a substantial amount of manual and laborious
efforts. For example, the design of PCR primers for fusion
validations needs to take into account many factors
including the original orientations of the two partner
genes on the chromosome(s), the orientation of the
fusion transcript, the 50 to 30 order of the two partners
in the fusion product, as well as the knowledge of the
mapping orientations of the read pairs. We developed a
robust bioinformatics pipeline for the identiﬁcation of
fusion transcripts in paired-end RNA sequencing
(RNA-Seq) data, which is part of Mayo Clinic’s
Next-Generation sequencing data analysis tool suite,
SnowShoes. We named this pipeline SnowShoes-FTD
(Fusion Transcript Detection). The analytical power of
this pipeline lies in a very low false detection rate (ap-
proaching 0%), thereby overcoming the major problem
that we and others have encountered in conﬁrmation of
candidate fusion transcripts. Moreover, SnowShoes-FTD
incorporates several subroutines to generate template
regions for PCR primer design, which facilitates quick
PCR validations, as well as the amino acid sequences of
the putative in-frame fusion gene products, which facili-
tates predictions concerning the functional signiﬁcance of
the fusion events. In addition, SnowShoes-FTD provides
likely fusion mechanisms (translocation, inversion and
deletion), strand orientation of fusion transcripts and
identiﬁes the mutations at the fusion junction points for
in-frame fusions. SnowShoes-FTD is publicly available
for download at web site: http://mayoresearch.mayo
.edu/mayo/research/biostat/stand-alone-packages.cfm.
MATERIALS AND METHODS
Breast cell lines
Twenty-two breast cancer cell lines and one
non-tumorigenic breast epithelial cell line (MCF10A)
were obtained from the American Type Culture
Collection (ATCC) (Table 1). All cell lines were thawed
and expanded to allow for the isolation of total RNA
from low passage cells, which should exhibit minimal de-
viation from the ATCC type reference cells. Eight primary
human mammary epithelial cell (HMEC) cultures were
established from biopsies of Mayo Clinic patients under-
going evaluation of suspected breast lesions (Table 1). All
the biopsy samples from which the cell lines were derived
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we will operationally deﬁne these cells as ‘normal’.
RNA preparation and sequencing
Total RNA extraction was performed using Exiqon’s
miRCURY RNA Isolation Kit. One microgram of total
RNA was used for the sequencing library preparation,
which was modiﬁed from conventional Illumina
mRNA-Seq protocols to facilitate paired-end RNA
sequence analysis (13). The cDNA fragments were
ampliﬁed by PCR and sequenced at both ends for 50
bases (50-bp-end sequencing) using the IGA IIx.
Sequencing was carried out at the Illumina assay develop-
ment facility at Hayward, CA, USA and at the Mayo
Clinic Advanced Genomic Technology Center at
Rochester, MN, USA. The FASTQ read ﬁles for each
sample were used for further analysis.
Construction of exhaustive one-directional exon junction
database
The exon–exon boundary database was generated using
the exon and gene deﬁnition ﬁles downloaded from
UCSC Table Browser (table: refFlat; track: RefSeq
Genes; group: Genes and Gene Prediction Tracks) in ref-
erence to human genome build 36 (hg18). Among 35983
total transcripts in the refFlat ﬁle, 765 transcripts with
alternative haplotypes and 1482 transcripts with
multiple/redundant genomic locations were removed.
Based on the exon boundaries of all transcripts deﬁned
in the curated refFlat ﬁle, all possible one-directional com-
binations of exon–exon boundary sequences for the
sequencing length of 50 bases were generated to ensure
that no reads will map to more than one junction using
an in-house developed algorithm (S. Middha, N. Hossain,
Y.W. Asmann, unpublished data). The curated refFlat ﬁle
and its future updated versions in reference to both
genome builds 36 and 37, as well as the FASTA ﬁles of
exon–exon boundary sequences for different sequencing
lengths (50-, 75- and 100-base) can be downloaded from
our web site: http://mayoresearch.mayo.edu/mayo/
research/biostat/stand-alone-packages.cfm.
The analytic workﬂow for fusion detection
As shown in Figure 1, the SnowShoes-FTD tool consists
of (i) read alignments to both reference genome and exon
junction database; (ii) annotation of aligned read pairs to
identify potential fusion candidates; (iii) ﬁltering of false
positive candidates; (iv) generation of a continuous
sequence region spanning fusion junction points for
PCR primer design for experimental validation; (v) pre-
diction of fusion mechanism; and (vi) prediction of the
in-frame versus out of frame fusion products and gener-
ation of the predicted protein sequences of the in-frame
fusion products based on known transcripts of the two
Table 1. Sample information of the 31 breast cell lines
Sample number Sample ID Sequencing location Sample description Flow cell lane Run number
1 BT-474 Illumina Hayward, CA, USA Cancer Cell Line 1 Run #1
2 MCF10A Non-Tumorigenic 2
3 BT-20 Cancer Cell Line 3
4 MCF7 Cancer Cell Line 4
5 MDA-MB-468 Cancer Cell Line 6
6 T47D Cancer Cell Line 7
7 ZR-75-1 Cancer Cell Line 8
8 HCC1937 Mayo Clinic Sequencing Core Cancer Cell Line 1 Run #2
9 HCC1954 Cancer Cell Line 2
10 HCC2218 Cancer Cell Line 3
11 HCC1599 Cancer Cell Line 4
12 HCC1395 Cancer Cell Line 5
13 BT549 Cancer Cell Line 6
14 Hs578T Cancer Cell Line 7
15 MDA-MB-175V-II Cancer Cell Line 8
16 MDA-MB-361 Mayo Clinic Sequencing Core Cancer Cell Line 1 Run #3
17 MDA-MB-436 Cancer Cell Line 2
18 MDA-MB-453 Cancer Cell Line 3
19 SK-BR-3 Cancer Cell Line 4
20 UACC812 Cancer Cell Line 5
21 HCC1187 Cancer Cell Line 6
22 HCC1428 Cancer Cell Line 7
23 HCC1806 Cancer Cell Line 8
24 DHF 168 Illumina Hayward, CA, USA Normal HMEC* 1 Run #4
25 BSO19B Normal HMEC 2
26 BSO28 Normal HMEC 3
27 BSO29 Normal HMEC 4
28 BSO30 Normal HMEC 5
29 BSO32N Normal HMEC 6
30 BSO36 Normal HMEC 7
31 BSO37 Normal HMEC 8
HMEC, human mammalian epithelial cells primarily cultured from benign breast biopsy samples.
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mapped with poor quality as described above.
Read alignment and ﬁltering for fusion detection. The two
ends of RNA-Seq reads were aligned to both the Human
Reference genome build 36 (hg18) and exon junctions
using Burrows-Wheeler Alignment (BWA) (14) with a
seed length of 32 allowing 4% of maximum edit
distance. The BWA aligned reads are stored in the
Sequence Alignment/Map (SAM) format (15). The pair
of SAM ﬁles from the alignment of two ends of the
same sample were sorted according to read IDs using
SAMtools (15). The reads with neither end mapped to
genome or exon junctions are not informative and were
ﬁltered out. If the Phred-scaled Mapping Quality Score
(MAPQ) of either end was <20, the end pair is considered
low quality and was excluded from further analysis. Note
that this will also ﬁlter out read pairs with either or both
ends mapped to multiple locations since BWA assigns a
MAPQ of zero to such reads.
Annotation of aligned reads. After ﬁltering, the reads re-
maining in the SAM ﬁles were categorized into ﬁve
groups: (i) reads with both ends mapped to genome loca-
tions; (ii) reads with both ends mapped to exon junctions;
(iii) reads with one end mapped to the genome and the
other mapped to exons; (iv) reads with one end mapped to
the genome and the other end not mapped; (v) reads with
one end mapped to exon junctions and the other not
mapped. All mapped ends were annotated using the
genes and exons deﬁned in the curated refFlat ﬁle. For a
read to be annotated as being mapped to a gene, we
required that either the start or the end of the read be
mapped within the boundaries of an exon of that gene.
If a read aligned to both genome and an exon junction, the
annotation from the exon junction alignment takes
precedence.
False positive ﬁltering. There are two steps of ﬁltering to
minimize the false fusion rate that has plagued nomination
of fusion gene candidates. The ﬁrst ﬁltering step is per-
formed on the reads pairs that are annotated to two dif-
ferent genes, also known as fusion encompassing reads.
This begins with the ﬁltering of fusion candidates with
signiﬁcant sequence similarities between the two fusion
partners (Please refer to the SnowShoes-FTD user
manual for details). In addition, a gene distance ﬁlter is
implemented to exclude fusions formed by two genes that
are within M kb of each other on the reference genome, in
order to eliminate chimeric transcripts that might arise
from overlapping genes or transcriptional read through
of adjacent genes. Furthermore, the fusion candidates
with less than N fusion encompassing reads are ﬁltered
out. The second ﬁltering step focuses on the fusion candi-
dates with supporting evidences of both fusion encom-
passing read pairs and fusion junction spanning reads.
Read Alignment to Genome Read Alignment to Exon Junctions
Both Ends Mapped to Genome 
and/or Exon Junctions
One End Map to Genome or Junction; 
The 2nd End Not Mapped
Both Ends 
Not Mapped
Filtered
Reads
Fusion Gene Nominees
Keep Read Pairs with One End Mapped to A
Fusion Partner, and the Other End Not-Mapped False Positive Filtering
Align the Not-Mapped Ends 
to Both Fusion Partners
Find Junction Spanning Reads Find Fusion Encompassing Reads
Keep Read Pairs Mapped
to Different Genes
List of genes as potential 
fusion partners
False Positive Filtering
Identify PCR Primer Design 
Region For Fusion Validation
Predict the Potential Fusion 
Mechanism: Translocation, 
Inversion, and/or Deletion
Calculate Putative Fusion 
Transcripts and Identify In-
Frame Fusions
Calculate the Amino Acid 
Sequences of the In-Frame 
Fusion Proteins
Figure 1. The work ﬂow of the fusion detection algorithm implemented in SnowShoes-FTD.
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to the orientations of the two fusion partner genes on the
genome, and the fusion candidates with inconsistent
mapping orientations between end pairs are ﬁltered out.
Also, the algorithm requires at least X unique fusion
junction spanning reads and no more than Y fusion
junction points per fusion candidate. Note that these
thresholds (M, N, X and Y) are user deﬁned.
Prediction of the fusion mechanism. If a fusion product is
formed by two partner genes from two different chromo-
somes, a translocation will be listed as the mechanism of
fusion. The translocation event can be accompanied by
inversion of the two partner genes that have the
opposite strand orientations. When the two partner
genes are located on the same chromosome, the mechan-
ism of the fusion could be translocation alone, inversion
alone and inversion and translocation concurrently. These
three scenarios are determined based on the strand orien-
tations and the relative chromosomal positions of the two
partners. However, when an intra-chromosomal fusion
arises without altering the relative orders of the two
partners with the same strand orientation, the fusion can
be the consequence of a translocation or an interstitial
deletion.
Prediction of the fusion protein product. Prediction of the
fusion protein sequences was carried out using all of the
known transcripts of the two fusion partner genes as
deﬁned in the refFlat ﬁle. As shown in Figure 3, we ﬁrst
identify the two exons from each of the two fusion partner
genes that aligned to the fusion spanning reads (fusion
boundary exons). Next, among all know transcripts of
the two fusion partner genes, we identify the transcripts
containing the boundary exons and generated a list of
putative fusion transcripts. Each of the putative fusion
transcripts was then translated into predicted amino acid
sequence and each of the putative fusion proteins
characterized as whether it is in frame. In addition, the
fusion products are categorized as: (i) coding region to
coding region fusion which will result in in-frame fusion
product, a frame shift for the 30 gene or an in-frame fusion
with a single amino acid mutation at the fusion junction
point. The single amino acid mutation will be listed in the
SnowShoes-FTD output; (ii) 50-UTR to coding region
fusion in which the promoter of the 50-gene fused in
front of a coding region of the 30-gene; (iii) 50-UTR to
30-UTR fusion in which coding regions from both
partner genes are fused out; (iv) 30-UTR to 30-UTR
fusion in which the 50-gene are intact but the coding
region of the 30-gene is fused out; (v) 50-UTR to 50-UTR
fusion in which the promoter of the 50-gene will potentially
drive the expression of 30-gene as the consequence of the
fusion; (vi) 30-UTR to 50-UTR or coding region fusion in
which the stop codon of the 50-gene will terminate the
translation of any coding regions of the 30-gene;
(vii) coding region to 50-UTR fusion in which the
sequence between the coding region of the 50-gene and
the start codon of the 30-gene may result in an insertion
of single or multiple amino acids that are listed in the
output ﬁle; (viii) the coding region to 30-UTR fusion
which may result in the shortening of the 50-gene with or
without the addition of foreign amino acids.
Nucleotide sequences spanning fusion junction points for
PCR primer design. The chromosomal orientations of
the two fusion partners, the mapping orientations of the
two ends from fusion encompassing read pairs, as well as
the sequence and orientation of the fusion junction
spanning read(s) are used to report a template region for
PCR primer design in order to quickly validate the fusion
candidates with RT–PCR. From 50–30, the template region
consists of the exon region from partner A from the start
of the exon to the fusion junction point, a ‘||’ sign that
signiﬁes the fusion junction point and the exon region
from partner B from the start of the fusion junction
point to the end of the exon. Since the orientation of the
primer template region does not necessarily deﬁne direc-
tionality (50 to 30) of the fusion transcript, it is necessary to
use double-stranded cDNAs as the template for PCR
validation.
PCR and Sanger sequencing validations of fusion
candidates
Double-stranded cDNA were synthesized using the total
RNAs from each of the 31 cell lines. It should be noted
that, to minimize potential artifacts that might arise
during library construction, different cDNA libraries
were constructed and used for sequencing and for PCR
validation. PCR primers were designed using the template
regions recommended by SnowShoes-FTD. The 50 and 30
primers were complementary to the template regions that
represent the two fusion partners, respectively. The fusion
transcript is considered validated if we detected a PCR
product of the predicted size. The PCR bands from
randomly selected fusion transcripts were sequenced
using Sanger sequencing to further conﬁrm the nucleotide
sequence of the predicted fusion junctions.
Quantiﬁcation of gene and exon expression levels
The gene expression levels were calculated as the sum of
the individual exon read counts and exon junction read
counts. The expression levels of genes and exons were
normalized using the total aligned reads from the sample
and the length of the exon or gene (Reads per kilo bases
per million, RPKM).
RESULTS
Flexibility of the choice of sequence alignment tools
Currently, there are several sequencing platforms and
multiple sequence alignment algorithms designed for
next-generation sequencing of transcriptome. The
SnowShoes-FTD can work with raw or post-alignment
ﬁles of different platforms. When FASTQ ﬁles obtained
from IGA or HiSeq sequencers are provided as input, the
users can choose BWA or Bowtie (16) for alignment. We
also accept post-alignment ﬁles (BAM) for both genome
and exon junction alignments from a different sequencing
platforms including Life Technologies’ SOLiD sequencer.
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SnowShoes-FTD over other publically available junction
databases, the user will need to align the reads to the exon
junctions provided by SnowShoes-FTD if BAM ﬁles are
provided as input ﬁles. The results reported in the current
manuscript were obtained using FASTQ as input ﬁles and
BWA as the aligner.
User-deﬁned parameters for SnowShoes-FTD
The following parameters are user-deﬁned for detection of
fusion transcripts using SnowShoes-FTD: (i) the
minimum number of fusion encompassing reads (default
value: 10); (ii) the minimum number of unique fusion
junction spanning reads (must be  1 with a default set
to 2); (iii) the minimum distance between the two fusion
partner genes if both are located on the same chromosome
(default value: 100 kb); (iv) the maximum number
of fusion isoforms allowed between two fusion partners
(default value: 2); and (v) whether the fusion tran-
scripts feature junction points at exon boundaries
(default=Yes). The default values of the parameters
were chosen to minimize false positive rate. For
example, the minimum number of unique fusion
junction spanning reads was set to 2 by default to avoid
the false detection of fusion junction spanning reads
arising form the PCR artifacts, which may give multiple
junction spanning reads that are identical in alignment
positions. In addition, the limit of the maximum fusion
isoforms between two partner genes is based on the
hypothesis that if there are too many fusion isoforms
between two partners, the fusion event would appear to
be existing by random fusion events without obvious
biological signiﬁcances.
List of reference ﬁles available
A list of reference ﬁles is available for download in prep-
aration for the fusion transcript detection using
SnowShoes-FTD: (i) the one-directional exhaustive
exon–exon junction database generated for read-lengths
50-, 75- and 100-bases. This is provided in the FASTA
format; and (ii) the curated gene and exon deﬁnition
ﬁles (refFlat ﬁles) from both genome builds 36 and 37.
The gene and exon deﬁnition ﬁles will be updated period-
ically. All reference ﬁles can be obtained from the
SnowShoes web site: http://mayoresearch.mayo.edu/
mayo/research/biostat/stand-alone-packages.cfm.
Detection of fusion transcripts in 31 breast cell lines
We applied the SnowShoes-FTD tool to the 50-bp-end
RNA-Seq data from 22 breast cancer cell lines, 1 estab-
lished non-tumorigenic breast cell line (MCF10A) and 8
primary HMEC cultures (Table 1). The fusion transcript
candidates of these 31 breast cell lines were nominated
using the default parameter values based on genome
build 36 (hg18). As shown in Supplementary Table S1,
read pairs sequenced per sample total to 18–33 millions,
among which: 45–58% have both ends mapped to the
genome; 3–5% have both ends mapped to exon junctions;
11–18% with one end mapped to the genome and the
other mapped to exon junctions; 5–15% with one end
mapped to the genome and the other not mapped; and
1–2% with one end mapped to exon junctions and the
other not mapped. In addition, there are 2–9% of the
read pairs with neither ends mapped to the genome or
exon junctions. In all, 11–20% of the reads were ﬁltered
out due to low mapping quality and/or redundant
mapping.
We nominated 55 fusion transcript candidates (Table 2
and Supplementary Data S2). Fifty of these have unique
isoforms while the rest have two isoforms. As shown in
Figure 2a, all 50 fusion transcripts with a single fusion
isoform were validated as evidenced by the generation of
PCR products of the predicted sizes. We randomly picked
several fusion transcripts for further validation using
Sanger sequencing of the PCR bands. All PCR products
were conﬁrmed by Sanger sequencing with the observation
that the predicted DNA sequence conformed to the actual
DNA sequence of the PCR product (data not shown). All
isoforms were similarly validated for the ﬁve fusion can-
didates with two isoforms (Figure 2b). The sequences of
the primers used in PCR validations can be found in
Supplementary Data S4, which includes the primers for
the alternative isoforms of the ﬁve fusion candidates
with two isoforms each.
Among the 55 fusion candidates, 30 were in-frame
(Table 2 and Supplementary Data S3). We deﬁne a
fusion product as ‘in frame’ when there was no frame
shift in the 30-gene, regardless whether there is single
amino acid mutation or single/multiple amino acid inser-
tion at the fusion junction point. The fusion junction point
mutations are also listed in the Supplementary Data S3. In
addition, the list of fusion transcripts as the result of ex-
haustive combinations of all transcripts from two partner
genes may contain identical fusion products if the differ-
ences between the transcripts from the same partner are
‘fused out’. For example, as shown in Figure 3d, the
fusion transcript of A1-B4 is identical to that of A1-B1,
and the fusion transcript of A2-B4 is identical to that of
A2-B1. These identical fusion proteins are ﬂagged in the
SnowShoes output ﬁle (Supplementary Data S3).
Fusion genes identiﬁed in MCF7 cancer cell line
Fusion gene products in the MCF7 cell line had been pre-
viously described using a paired-end sequencing protocol,
so we compared the list of fusion transcripts identiﬁed in
MCF7 cancer cell line using SnowShoes-FTD with those
identiﬁed by Maher et al. (6). The SnowShoes-FTD
identiﬁed and validated ﬁve novel fusion transcripts that
were not reported by Maher et al.: ADAMTS19-
SLC27A6, ATXN7L3-FAM171A2, GCN1L1-MSI1,
MYH9-EIF3D and RPS6KB1-DIAPH3. In addition,
there were ﬁve fusion genes identiﬁed by Maher et al.
that were not detected by SnowShoes-FTD:
ARHGAP19-DRG1, BC017255-TMEM49, PAPOLA-
AK7, AHCYL1-RAD51C and FCHOL-MYO9B. We
found that (i) BC017255 is no longer in the RefSeq
RNA database; (ii) the distance between PAPOLA-AK7
is 65 kb which is smaller than the default setting of 100 kb.
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observed to support this fusion. Therefore, this fusion
transcript would only have been detected with a different
distance threshold and by reducing the default for fusion
spanning reads to 0; (iii) there are no junction spanning
reads in our data set for AHCYL1-RAD51C although we
did ﬁnd 10 fusion encompassing reads supporting the ex-
istence of this fusion transcript; and (iv) there was only
one fusion junction spanning read for FCHOL-MYO9B
and the default setting for SnowShoes-FTD is ‘at least two
unique junction spanning reads’. On the other hand, we
found no evidence in support of an ARHGAP19-DRG1
Table 2. List of fusion transcripts identiﬁed
Fusion transcript Mechanism Type In frame Strand Total read
pairs
Between exon
boundaries
No. of fusion
isoforms
Sample ID
LIMA1 ! USP22 T inter-chr Yes   16 Yes 1 BT-20
ACACA ! STAC2 T intra-chr Yes    72 Yes 1 BT-474
FAM102A ! CIZ1 T intra-chr   31 Yes 2 BT-474
GLB1 ! CMTM7 I intra-chr Yes   13 Yes 1 BT-474
MED1 ! STXBP4 I and T intra-chr Yes   54 Yes 1 BT-474
PIP4K2B ! RAD51C I and T intra-chr   15 Yes 1 BT-474
RAB22A ! MYO9B T inter-chr + 16 Yes 1 BT-474
RPS6KB1 ! SNF8 I and T intra-chr Yes + 162 Yes 1 BT-474
STARD3 ! DOK5 T inter-chr + 21 Yes 1 BT-474
TRPC4AP ! MRPL45 I and T inter-chr Yes   27 Yes 1 BT-474
ZMYND8 ! CEP250 I intra-chr   189 Yes 2 BT-474
CTAGE5 ! SIP1 T intra-chr + 64 Yes 1 HCC1187
MLL5 ! LHFPL3 T intra-chr + 23 Yes 1 HCC1187
PUM1 ! TRERF1 T inter-chr   58 Yes 1 HCC1187
SEC22B ! NOTCH2 I and T intra-chr + 22 Yes 1 HCC1187
EIF3K ! CYP39A1 I and T inter-chr Yes + 91 Yes 1 HCC1395
RAB7A ! LRCH3 D or T intra-chr + 14 Yes 1 HCC1395
RNF187 ! OBSCN T intra-chr + 11 Yes 1 HCC1428
SLC37A1 ! ABCG1 T intra-chr Yes + 20 Yes 1 HCC1428
CYTH1 ! PRPSAP1 D or T intra-chr Yes   33 Yes 1 HCC1599
EXOC7 ! CYTH1 T intra-chr Yes   20 Yes 1 HCC1599
BRE ! DPYSL5 T intra-chr Yes + 13 Yes 1 HCC1806
CD151 ! DRD4 T intra-chr + 11 Yes 1 HCC1806
LDLRAD3 ! TCP11L1 T intra-chr + 25 Yes 1 HCC1806
RFT1 ! UQCRC2 I and T inter-chr Yes   102 Yes 1 HCC1806
TAX1BP1 ! AHCY I and T inter-chr Yes + 54 Yes 1 HCC1806
NFIA ! EHF T inter-chr Yes + 18 Yes 1 HCC1937
GSDMC ! PVT1 I intra-chr   23 Yes 1 HCC1954
INTS1 ! PRKAR1B D or T intra-chr Yes   24 Yes 1 HCC1954
PHF20L1 ! SAMD12 I and T intra-chr Yes + 106 Yes 1 HCC1954
STRADB ! NOP58 D or T intra-chr Yes + 10 Yes 1 HCC1954
POLDIP2 ! BRIP1 T intra-chr   13 Yes 1 HCC2218
ADAMTS19 ! SLC27A6 T intra-chr + 30 Yes 1 MCF7
ARFGEF2 ! SULF2 I and T intra-chr Yes + 421 Yes 1 MCF7
ATXN7L3 ! FAM171A2 T intra-chr   10 Yes 1 MCF7
BCAS4 ! BCAS3 T inter-chr + 1697 Yes 1 MCF7
GCN1L1 ! MSI1 T intra-chr Yes   25 Yes 1 MCF7
MYH9 ! EIF3D T intra-chr Yes   16 Yes 1 MCF7
RPS6KB1 ! DIAPH3 I and T inter-chr + 25 Yes 1 MCF7
SULF2 ! PRICKLE2 T inter-chr   26 Yes 1 MCF7
ODZ4 ! NRG1 I and T inter-chr Yes   12 Yes 1 MDA-MB-175V-II
BRIP1 ! TMEM49 I intra-chr   28 Yes 1 MDA-MB-361
SUPT4H1 ! CCDC46 T intra-chr   17 Yes 1 MDA-MB-361
TMEM104 ! CDK12 T intra-chr Yes + 10 Yes 2 MDA-MB-361
RIMS2 ! ATP6V1C1 T intra-chr Yes + 11 Yes 1 MDA-MB-436
TIAL1 ! C10orf119 T intra-chr   12 Yes 1 MDA-MB-436
MECP2 ! TMLHE T intra-chr   29 Yes 1 MDA-MB-453
ARID1A ! MAST2 D or T intra-chr Yes + 18 Yes 1 MDA-MB-468
UBR5 ! SLC25A32 T intra-chr   28 Yes 1 MDA-MB-468
KLHDC2 ! SNTB1 I and T inter-chr Yes + 25 Yes 1 SK-BR-3
ARID1A ! WDTC1 D or T intra-chr Yes + 23 Yes 1 UACC812
HDGF ! S100A10 D or T intra-chr Yes   154 Yes 1 UACC812
PPP1R12B ! SNX27 T intra-chr Yes + 45 Yes 1 UACC812
SRGAP2 ! PRPF3 T intra-chr Yes + 22 Yes 2 UACC812
WIPF2 ! ERBB2 T intra-chr Yes + 66 Yes 2 UACC812
In the fusion mechanism column: T, translocation; I, inversion; D, interstitial deletion; Intra-chr, intra-chromosomal fusion; Inter-chr,
inter-chromosomal fusion. The fusion transcripts are named as the 50 gene ! 30 gene. For example, LIMA1 ! USP22 is a fusion transcript
formed between two partner genes, LIMA1 and USP22, in which LIMA1 is the 50 gene and USP22 is the 30 gene.
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read pairs that mapped to both of these genes. When we
performed RT-PCR using the PCR primers provided by
Maher et al. (Supplementary Data S5), the results also
supported the existence of the fusion products
BC017255-TMEM49, PAPOLA-AK7, AHCYL1-
RAD51C and FCHOL-MYO9B, while no PCR product
was observed for the ARHGAP19-DRG1 fusion. Thus, 4
out 5 ‘known’ fusion transcripts that were not identiﬁed
by SnowShoes-FTD can be explained by differences in the
RefSeq database used for the analyses or by the choice
of parameter settings for our various ﬁltering steps. The
ARHGAP19-DRG1 fusion transcript reported by Maher
et al. does not appear to be expressed in the MCF7 cells
that we have obtained from ATCC.
As our analyses were in preparation for submission,
Edgren et al. (12) reported on the detection of fusion tran-
scripts in four breast cancer cell lines, including MCF7 in
which three fusion transcripts were validated. We detected
eight fusion transcripts in MCF, including two of the three
reported by Edgren et al. (BCAS4_BCAS3 and
ARFGEF2_SULF2, both previously identiﬁed). Overall,
our results correspond reasonably well with those reported
by Edgren et al.
Pathway analysis of genes involved in fusion transcripts in
breast cancer cell lines
There were a total of 105 fusion partner genes from the 55
fusion candidates, among which 58 genes formed in-frame
fusion transcripts of 30 chimeric RNAs. We performed
pathway and regulatory network analyses of these 58
genes using MetaCore (GeneGo Inc., San Diego, CA,
USA). Two pathways that are enriched among these 58
genes: the non-genomic action of androgen receptor and
ligand-independent activation of ESR1 and ESR2. Three
GeneGo process network were signiﬁcantly enriched:
androgen receptor signaling cross-talk, ESR1-nuclear
pathway and FGF/ERBB signaling. This observation
suggests that fusion transcripts may have functional sig-
niﬁcance in signal transduction in breast cancer cells.
Figure 2. PCR validation of candidate fusion products. The PCR primers were designed using the template sequences generated by
SnowShoes-FTD. The double-stranded cDNA libraries were constructed using total RNAs from each of the cell lines. The primer sequences and
the expected PCR product sizes for each of the fusion candidates were detailed in Supplementary Data S4. (a) The PCR products from 50 fusion
candidates with unique isoforms. The fusion candidates were grouped by the cell lines in which the fusion candidates were discovered. (b) The PCR
products from ﬁve fusion candidates with two fusion isoforms each. Note that there are multiple PCR bands in the lanes for CDK12-TMEM104,
and the lowest bands were those from the fusion product.
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preponderance of ‘promoter swap’ mutations, one of which
may represent a novel mechanism for ERBB2
overexpression
The analytical power of the SnowShoes-FTD pipeline lies
in part in the very low false detection rate and in very large
part in the downstream features that predict the structure
of the hypothetical fusion transcripts and the amino acid
sequence of the resultant translation products. Such
analyses indicate that the nature of the fusion transcripts
that were detected in breast cancer cells is strikingly
non-random, as evidenced by the fact that 23 of the 60
conﬁrmed chimeric transcripts result from fusion of exon
1 of the 50/upstream partners to the 30/downstream
partners. The most probable cause of such chimeric
RNAs is a genomic rearrangement (12) that results in
juxtaposition of a promoter that potentially alters the
level of expression and/or the regulation of the down-
stream partner in response to changes in the cellular
environment. In addition, all the fusion transcripts that
we have reported and validated map precisely to exon/
exon junctions between the upstream and downstream
fusion partners, suggesting that such transcripts are pro-
cessed. There were only ﬁve additional fusion transcripts
in which the fusion junction points are in the middle of
exons (detected with different parameter settings for
SnowShoes-FTD, data not shown). About half of the
fusion events are in frame and therefore predicted to
encode fusion proteins. The preponderance of such
events in our samples suggests that some of the fusion
transcripts may convey a growth advantage, such that
transcript enrichment results from selection. For
example, MDA-MB-468 cells express an
ARID1A_MAST2 fusion transcript (Figure 4a) that
might result from translocation without inversion of the
ARID1A promoter (1p36.11) to the more centromeric
MAST2 locus (1p34.1) Alternatively, this fusion transcript
might result from interstitial deletion of those portions of
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Figure 3. The identiﬁcation of in-frame fusion transcripts and their predicted protein sequences. (a) Staring from the fusion junction spanning reads
that aligned to both fusion partner genes, the two junction boundary exons from fusion partner genes A and B are identiﬁed; (b) obtaining the IDs
and sequences of all exons belonging to the two fusion partner genes A and B based on the curated refFlat ﬁle. In this example, Gene A has 7 exons
with the third exon as the fusion boundary exon, and gene B has 10 exons with the sixth exon as the fusion boundary exon; (c) obtaining all known
transcripts for the two fusion partner genes. Gene A has two known transcripts (A1 and A2) both of which contain the fusion boundary exon. Gene
B has 4 known transcripts (B1 ! B4) and three of which (B1, B3 and B4) contain the fusion boundary exon. (d) Generating the list of exhaustive
fusion transcripts using the known transcripts containing the fusion boundary exons. There are six possible fusion transcripts: A1-B1, A1-B3, A1-B4,
A2-B1, A2-B3 and A2-B4. Note that because the differences between the transcripts B1 and B4 are ‘fused out’, the fusion transcript of A1-B1 is
identical to that of A1-B4. Similarly, A2-B1 is identical to A2-B4. The fusion transcripts that cause frame shift in gene B are deﬁned as ‘out of
frame’, and the ones that did not cause any frame shift will be deﬁned as ‘in frame’ fusions. Each of the in-frame fusions will be translated into
amino acid sequences of the fusion proteins.
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Figure 4. Detailed description of ARID1A_MAST2 (a) and WIPF2_ERBB2 (b) fusion transcripts. Using the process described in Figure 3,
SnowShoes-FTD uses the RNA sequence of all known transcripts of the fusion partners to predict the sequence of all potential in-frame and
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(coordinates 26896618) and exon 2 of MAST2 (coordin-
ates 46062691). Juxtaposition of the ARID1A promoter
would place control of MAST2 which is downstream of
the RB1 pathway, as evidenced by the preponderance of
E2F sites in the ARID1A promoter and by the observa-
tion that ARID1A is regulated in a cell cycle-dependent
manner (17). SnowShoes-FTD predicts that in-frame
fusion between ARID1A exon 1 and MAST2 exon 3
will give rise to a chimeric transcript with a predicted
open reading frame of 2118 amino acids. The
N-terminal 378 amino acids of this hypothetical fusion
protein are derived from ARID1A and appear to
contain no known or predicted functional domain.
Conversely, the C-terminal 1740 amino acids are derived
from MAST2 and contain the protein kinase, AGC kinase
and PDZ domains of the parental protein. It is likely that
this fusion protein has serine/threonine kinase activity.
Whether loss of the N-terminal 58 amino acids from
MAST2, insertion of the 378 amino acid N-terminus of
ARID1A or aberrant expression of MAST2 driven from
the ARID1A promoter conveys novel oncogenic potential
remains to be determined. However, MAST2 plays an im-
portant role in the regulation of NFkB activity down-
stream of TRAF6 (18), and a SNP within the MAST2
locus has been implicated in breast cancer risk (19). We
examined the exon level expressions of the fusion tran-
script. As shown in Figure 4a, exon 1 expression of
MAST2 was signiﬁcantly lower than the other exons
(exon 2–29), which might be due to the fact the exon 1
was fused out. However, there were no obvious expression
differences between the exons of the ARID1A gene.
The most provocative chimeric transcript that we have
detected involves fusion of the WIPF2 and ERBB2 RNAs.
Two isoforms of the fusion were predicted and validated.
These chimeric transcripts are expressed in UACC812
cells, which were derived from a HER2+ tumor (20).
The WIPF2 locus (also known as WIRE) is located at
chr17q21.2 and is transcribed toward the telomere.
ERBB2 is located at chr17q11.2, centromeric to WIPF2.
Like WIPF2, ERBB2 is transcribed toward the telomere.
It is therefore probable that this fusion transcript arises as
a result of translocation without inversion of the WIPF2
promoter to give rise to two in-frame transcripts in which
the 50-untranslated region of WIPF2 is fused to one of
several 50-untranslated exons of ERBB2 (Figure 4b). The
genomic structure of this hypothetical translocation
remains to be veriﬁed, but the net result of such an
event would be to place ERBB2 expression under
control of a promoter that appears, from analysis of po-
tential transcription factor binding sites in the WIPF2 50
ﬂanking region, to be susceptible to regulation by NFkB,
NOTCH and MYC signaling. It is tempting to speculate
that this hypothetical promoter swap may account, at
least in part, for the observation that ERBB2 transcripts
account for about 12632 tags per million total tags, as
determined from our mRNA-Seq data, which translates
to about 1.3% of the total polyA+ mRNA pool in
UACC812 cells. The observation that there is a dramatic
increase in ERBB2 exon expression at the fusion junction
(Figure 4b) is consistent with this hypothesis.
SnowShoes-FTD predicted two WIPF2_ERBB2 fusion
junctions which were veriﬁed in UACC812 cells: WIPF2
chromosomal coordinates 35629270 fused to ERBB2 co-
ordinates 35104766 or 35116768. The latter coordinates
fall within the coding sequence of one of the RefSeq
variants of ERBB2 mRNA (exon 2 of NM_004448) and
would introduce a frame shift mutation in that variant
(Figure 4b). However, two of the three predicted fusion
sequences (composed of exon 1 of WIPF2 NM_133264
fused to exon 4 or 5 of ERBB2 NM_001005862) would
produce transcripts that encode full-length ERBB2
protein (Figure 4b). Unfortunately, it is not possible at
this time to determine the sequence of full-length tran-
scripts from mRNA-Seq data. Consequently, it will be
necessary to clone and sequence longer cDNA fragments
that correspond to the ﬁrst few hundred nucleotides of the
fusion transcript in order to determine which of the hypo-
thetical transcripts are expressed. When we examined the
exon expression levels of ERBB2, exons 1–4 are substan-
tially less abundant than downstream exons, suggesting
that the transcript with the ﬁrst 4 exons of ERBB2 fused
out might be the more plausible fusion product.
Several cautionary notes warrant emphasis in this dis-
cussion of ERBB2 fusion transcripts. We are inclined to
believe that such transcripts arise as a result of genomic
rearrangement, although our data do not exclude alterna-
tive mechanisms. The relative position of the two tran-
scription units on chromosome 17 precludes read
through transcription as a potential mechanism to
generate the WIPF2_ERBB2 (but not the
ARID1A_MAST2) transcripts. However, it is formally
possible that some of these chimeric transcripts may
arise by trans-splicing events. Genomic sequencing of the
relevant loci will be required to rigorously deﬁne the
mechanism that gives rise to any of these potentially im-
portant fusion transcripts. It will also be necessary to de-
termine if there is ampliﬁcation of the WIPF2-ERBB2
fusion gene in UACC812 cells, if these cells retain intact
ERBB2 alleles and if these are also ampliﬁed. Until these
questions are resolved, it will not be possible to say with
any conviction that overexpression of ERBB2 in these
cells results from a promoter swap mutation.
Nevertheless, we are intrigued by the notion that our
analyses may have identiﬁed a novel mechanism that
accounts for ERBB2 overexpression in HER2+ breast
cancer.
DISCUSSION
It has been our experience, as well as that of other inves-
tigators, that the predominant analytical issue in detection
of fusion transcripts from paired-end mRNA-Seq data is
high false detection rate. Different approaches have been
proposed to deal with this issue. Wang et al. (21) proposed
that the fusion events in a certain type of tumor/disease
are more likely to arise from genes with similar functions;
therefore, one can prioritize fusion candidates based on
pathway and/or gene ontology analyses. Others have
ﬁltered out the false fusion candidates with homology
between fusion partners, with adjacent/overlap partners
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spanning reads (6,7,12). The SnowShoes-FTD implements
similar false positive ﬁltering steps, as well as additional
ﬁlters including the requirement of the consistencies
between the mapping orientations of the end pairs and
the two fusion partners, and capping the maximum
number of fusion junction points between two fusion
partners. Implementation of these features leads to the
identiﬁcation of a subset of high-conﬁdence candidates,
as evidenced by our ability to conﬁrm 100% of the
putative fusion transcripts described in this study.
The results reported in this manuscript were generated
using a set of default parameter values that were deﬁned to
minimize the false positive rate. The sensitivity and false
positive rate are inﬂuenced by all four user-deﬁned par-
ameters. It is very difﬁcult to provide a matrix of the sen-
sitivity versus FDR using different settings of the
parameters. For example, by not requiring fusion
junction spanning reads (parameter ii), the number of
fusion candidates increased from 8 to 50 in MCF7 cells.
In addition, if we set parameters to accept candidates with
no fusion junction spanning reads, SnowShoes-FTD
cannot generate a PCR primer template for quick
RT-PCR validation, which makes the validation of the
additional fusion candidates difﬁcult. Since the PCR val-
idation is required for accurately calculating the sensitivity
and FDR, we chose to give the users the ﬂexibility of ad-
justing the parameters rather than dictating the input par-
ameters by providing a sensitivity/FDR matrix.
A comparison of our results with those reported for
MCF7 in two previous studies reveals a high degree of
correspondence, but emphasizes the fact that a signiﬁcant
factor in the outcome of all analyses of this sort resides in
the user-deﬁned abundance thresholds for selecting candi-
dates for validation. This observation raises a signiﬁcant
consideration about depth of sequencing. Most of these
chimeric transcripts are of low abundance, and the fusion
junction point is a small ‘target’. All published fusion gene
analysis of breast cancer cells to date have been done with
relatively low depth of sequencing, which introduces a
certain level of chance that one will, in a given sequencing
run, be able to detect two or more tiled fusion spanning
reads. We posit that a complete proﬁle of fusion tran-
scripts will likely require a greater depth of sequence
analysis than has achieved to date. A more comprehensive
proﬁle should emerge from transcriptome sequencing with
the newer Illumina Hi-Seq 2000 platform, which routinely
yields >100M tags/lane.
Additional sources of variation may include intrinsic
differences in the cell lines used in the analyses. It is well
known that tumor cell lines exhibit genomic drift, which,
in combination with different growth conditions in differ-
ent laboratories, may result in signiﬁcant divergence
between cell lines maintained in different laboratories.
Since genomic instability is probably the driving force
behind generation of fusion transcripts, it is plausible
that the cells with the greatest genomic instability will
not only have the greatest number of fusion transcripts,
but are also likely to be more variable in this respect from
laboratory to laboratory. Cognizant of this possibility, we
elected to use only cell lines that were recently thawed
from ATCC reference cultures and maintained in culture
for no longer than necessary to isolate RNA for library
construction and sequence analysis. Implicit in this line of
reasoning is the idea that many of the fusion transcripts
that we and others have identiﬁed in cell lines may have
arisen after isolation of the cell lines and may not reﬂect
the fusion transcript proﬁle that was obtained in the
primary tumor from which these cells were initially
isolated. If this hypothesis is correct, we would expect to
see fewer fusion transcripts in primary tumor samples.
Our preliminary analyses suggest that this proposition is
likely correct (data not shown).
There are many distinctive features of SnowShoes-FTD
compared with other pipelines. Some of these features
reﬂect our decision at the outset to make this pipeline
ﬂexible as to input format and user-deﬁned ﬁlter param-
eters, as user friendly as possible, and freely available to
any investigator who wishes to use it. In developing
SnowShoes-FTD, we were motivated by the concept that
downstream analysis of candidate fusion transcripts
would require not only a low FDR, but also a set of
tools that would make testable predictions about fusion
transcript structure and function. For this reason, we de-
veloped and incorporated tools that output a number of
key features of each fusion transcript. At the validation
stage, the most useful of these features is the predicted
nucleotide sequence at the fusion junction. This informa-
tion facilitates rapid design of PCR primers for veriﬁca-
tion of candidate transcripts. In addition, knowledge of
the fusion junction sequence permits relative straightfor-
ward output of a number of key structural features of the
chimeric RNA, including relationship to known exons and
genomic coordinates of the fusion junction. These features
are included in the output, making it a rather simple
matter to scan the data for chimeric RNAs that may
result from either promoter or 30-UTR swaps.
Knowledge of the fusion junction sequence is also
critical for predicting frame shifts or substitution muta-
tions that might attend fusion events. We also designed
the analysis to provide predicted transcript structures that
correspond to all known variants of both the upstream
and downstream partners. This information is particularly
critical in the case of upstream partners that exhibit alter-
native promoter utilization (different exon 1 coordinates),
as well as evaluation of the relationship between the fusion
junction and the translational start site of downstream
partners (namely, WIPF2_ERBB2). This output deﬁnes
the scope of alternative forms of the fusion tran-
script and, in cases of multiple forms of the downstream
partner, may identify critical questions that can only
be resolved by conventional cDNA cloning and
sequencing.
One of the features of fusion transcripts identiﬁed here
is that the structure of these chimeric RNAs is strikingly
non-random. We see a preponderance of transcripts that
may arise due to promoter swap mutations as well as a
signiﬁcant number of transcripts in which the C-terminal
sequence of the upstream partner as well as the nucleotide
sequence of the 30-UTR has been altered. Similar results
were reported by Edgren et al. (12). Clearly changing
the promoter or the 30-UTR may have considerable
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C-terminal amino acid sequence of the fusion protein
may affect function in a variety of ways. Based on these
considerations, we posit that the non-random nature of
the events that we have observed is likely to be due to
selection for altered function leading to growth advantage.
This prediction must be tested, of course, and experiments
to that end are in progress. But based upon what is known
about fusion gene products in hematopoietic malignancy,
we believe that it is most likely that breast cancer fusion
transcripts arise from genomic rearrangements (rather
than read through transcription or trans-splicing), that
these events are themselves largely random, that some of
these rearrangements give rise to fusion transcripts with
novel oncogenic properties and that cells that express
these RNAs are selected for growth. Analysis of array
comparative genomic hybridization data by Edgren et al.
(12) is consistent with this hypothesis.
Finally, our analysis has focused largely on fusion tran-
scripts that are likely to be translated into fusion proteins
that may exhibit altered function. It is likely that frame
shift transcripts may be rapidly degraded and therefore
difﬁcult to detect at the depth of sequence analysis that
we have generated. About half of the fusion events that we
have detected appear to impose premature termination of
translation. These may be of considerable signiﬁcance if
the open reading frame of the upstream partner encodes a
potentially functional protein. From a translational stand-
point, fusion transcripts are virtually certain to be tumor
speciﬁc, and even non-functional chimeric RNAs may be
useful as tumor biomarkers. Furthermore, out of frame
fusion events effectively silence one allele of two different
genes and might contribute to haploinsufﬁciency or be
associated with loss of heterozygosity of one or both of
the un-rearranged alleles. We have also noted that several
of these putative rearrangements may affect the expression
of intragenic microRNAs. For example, the miR-
1204-1207 family is intragenic to the 50-end of PVT1
(8:128,875,961-129,182,407), which is ‘fused out’ of the
GSCMC_PVT1 chimera in HCC1954 cells. This fusion
transcript probably results from an intrachromosomal in-
version which likely results in deletion of the microRNA
loci associated with the rearranged allele. The functional
signiﬁcance of fusion mutations in breast cancer remains
to be determined. At this point, it is clear that we now
have the analytical ability to begin to look at primary
tumor samples and to determine the prevalence, origin,
druggability and role of fusion transcripts in the natural
history of breast cancer.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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